



WHO Should Attend?

The congress is intended for chemists, physicists, technologists, physicians, and all scientists and clinicians interested in translational research and current state-of-the-art molecular imaging using Ga-68 PET radiopharmaceuticals and radionuclide therapy.



Registration

Breakfast, lunch and two coffee breaks are included each day

	Advance Registration (on or before January 30, 2015)	Regular Registration (after January 30, 2015)
Physicians	\$625 USD	\$725 USD
Resident/Fellow/Technologist/ Allied Health Professional*	\$525 USD	\$625 USD

*with verification of status

A limited number of needs based travel grants will be available. Visit wcga68.org for more information.



ABOUT Baltimore, Maryland*

Located only one hour from Washington, DC, Baltimore—the colorful, diverse city that is Maryland’s largest city and economic hub—is known for its beautiful harbor; quirky, distinct neighborhoods; unique museums, and the world-renowned Johns Hopkins Hospital.

Visit www.snmmti.org/wcga68 for more information on hotel accommodations, as well as transportation options from area airports in both Baltimore and Washington, DC.


**courtesy of www.baltimore.org.*

Interested in receiving more information about this event?

Visit www.snmmti.org/wcga68 or
email info@wcga68.org


3rd Theranostics World Congress on Ga-68 and PRRT

MARCH
12-14
2015



Johns Hopkins Medicine • Baltimore, Maryland




www.snmmti.org/wcga68



CONGRESS Overview

This congress will provide updates on recent developments in the exciting field of Theranostics for NETs, Prostate Cancer, and beyond. Experts from around the world will discuss their research and experience in this exciting field.

The term THERANOSTICS epitomizes the inseparability of diagnosis and therapy, the pillars of medicine, and takes into account personalized management of disease for a specific patient. Ga-68-radiolabeled and therapeutically labeled somatostatin receptor ligands have been used to image neuroendocrine tumors (NETs) clinically in Europe for nearly a decade. Efforts to obtain approval of these ligands in the US have increased in the past two years. With the potential of approved agents broadly available in the near future, this conference will be particularly useful to those who are new to Ga-68 PET theranostics radiopharmaceuticals. NETs are just the beginning; experts will discuss new research in innovative applications for Ga-68 PET radiopharmaceuticals, including PSMA and CXCR4 targeted imaging and therapy of prostate and other cancers.



CALL for Abstracts

The Call for Abstracts for the 3rd Theranostics World Congress (3TWC) on Ga-68 and PRRT is open until November 15, 2014.

Accepted original research presentations and poster sessions will be included in the main agenda for the Congress.

Visit www.snmni.org/wcga68 for details.

AGENDA

Thursday, March 12, 2015

Generators, Post-Processing, and Synthesis Modules
Chelators and Labeling Chemistry for Theranostic Isotopes
Theranostic Targeting Vectors

Friday, March 13, 2015

Peptide Receptor Radiotherapy – Status Quo and Where to Go
Targeting Prostate Cancer: Imaging and Therapy
Established and Innovative Applications for Diagnosis and Therapy

Saturday, March 14, 2015

State of the Art Management of NETs – Clinician and Patient Perspectives
Imaging with Gallium – From D to T (Diagnosis to Therapy)
How to Deliver Theranostics

PROGRAM Committee

- Richard Wahl, Co-Chair
- Horacio Amaral (Chile)
- Michael Graham (USA)
- Peter Herscovitch (USA)
- Michael Hofman (Australia)
- Ulrich Keller (Germany)
- Michael Lassmann (Germany)
- Helmut Mäcke (Germany)
- Corina Millo (USA)
- Richard Baum, Co-Chair
- Thomas O'Dorisio (USA)
- Frank Roesch (Germany)
- Mike Sathekge (South Africa)
- Michael Schultz (USA)
- Baljinder Singh (India)
- Ronald Walker (USA)
- Wolfgang Weber (USA)